Electronic prescribing: ready for prime time?

Abstract

Escalating drug expenditures and the prevalence of medication errors have prompted calls for drug cost control and quality improvement. E-prescribing promises to address these concerns. This study aims to describe the benefits and costs of eRx as assessed by key industry stakeholders, identify the components of a needed electronic prescribing infrastructure and the barriers to its completion, and identify potential public and private policies and initiatives that could encourage the development of an EPI and hasten eRx adoption among stakeholders.